Mohs Surgery

A cancer removal method that checks the whole surgical margin during the appointment instead of sending it away and waiting for a report. The surgeon removes a thin saucer of tissue containing the visible tumor plus a narrow rim around and beneath it. That piece goes to a laboratory in the same office, where it is frozen, sliced and stained, and the surgeon reads the slides. The slices are cut so the entire outer surface of the piece, all of the edges and the underside, appears on the slide. That is what makes this different from ordinary pathology. If tumor reaches an edge, the surgeon marks exactly where on a drawn map of the wound and removes another layer from that one place only. Everywhere the margin was clear is left alone. The cycle repeats until no tumor remains at any edge. The wound is then repaired, usually the same day: stitching the edges together in a line, moving a flap of neighboring skin, covering it with a skin graft, or leaving it to heal open. The surgeon is both surgeon and pathologist for the case, which is why Mohs surgeons complete an additional fellowship after dermatology residency.

Ordinary excision pathology examines slices taken across the specimen at intervals, rather like slicing a loaf and looking at a few of the cut faces. That samples the margin. It is a good sample, and it can miss a narrow root of tumor running between two slices.

Mohs uses a different geometry. The tissue is removed at a shallow angle and flattened so the edges and the deep surface lie in one plane, then frozen and sliced horizontally from the bottom. The first sections show the complete outer surface of what was taken. Nothing at the margin goes unexamined.

Why following the roots works: Basal cell and squamous cell carcinomas usually grow in continuity, as a connected mass with irregular roots, rather than jumping to separate spots. Following a root that appears at one edge leads reliably to the rest of it, and where the margin is clear there is nothing left behind to find.

The mapping is the other half. The specimen is divided, its edges marked with colored dyes, and drawn on a diagram of the wound. When tumor shows at one point on a slide, the surgeon knows which part of your wound that is and takes more tissue from there and nowhere else. That is how the method removes the least normal skin, and it is precise about direction, not only about depth.

Frozen sections, same day: Because the sections are frozen rather than processed in wax overnight, the answer comes back in under an hour, which is what allows the whole thing to happen in one visit. It is also why the tissue quality is lower than ordinary pathology and why reading it well takes specific training. Frozen sections work well for basal cell and squamous cell carcinoma. They are harder for melanoma, which is why melanoma is handled differently and often needs additional stains.

The surgery is unchanged. Frozen sections read the same, tumor is tumor, and the cure rate does not depend on skin tone. Every difference is in how the skin heals and how the scar looks.

Keloids and thick raised scars: More common in people with deeper skin tones, and more likely again on the chest, shoulders, upper back, jawline and earlobes. Mohs is done most often on the face, where keloids are less common, but ear and jaw tumors are not rare. If you have ever had a keloid, say so before the surgery. It changes how the wound is closed, whether tension is taken off the line with extra deep stitches, and whether the scar is treated preventively with silicone or steroid injections from early on.

Dark marks along the scar: Post-inflammatory hyperpigmentation, a brown or gray mark where skin has been inflamed, is common along the scar line in the first months and usually fades over six to twelve months. Sun makes it darker and slower to clear, so covering the scar or using SPF 30 or higher over it for a year genuinely matters.

A permanently lighter line: Hypopigmentation also happens and shows more against deeper skin tones. It is less common than the darkening and less likely to fade.

A separate point about getting here at all. Skin cancer is less common in people with deeper skin tones and is more often diagnosed late. It also appears more often on skin that is not sun-exposed: the palms, the soles, under nails, and the mouth and genital skin. A sore that does not heal, a spot that bleeds and reopens, or a new dark streak in a nail deserves a look regardless of skin tone. Late diagnosis is not a biological difference. It is a gap in who gets examined.

There is nothing to keep having. Mohs is a single definitive treatment, not a course, so it does not wear off and there is no maintenance version of it.

Stopping the follow-up: That is the risk here. Cure is commonly quoted around 99 percent for a previously untreated basal cell carcinoma, which is excellent and is not 100 percent. Recurrence usually appears within the first few years at the edge of the scar, as a small pearly bump, a spot that scabs and reopens, or a firm area under the line.

A new cancer somewhere else: This is the larger issue. After one keratinocyte skin cancer the chance of a second is high, and for most people that, rather than recurrence, is what the follow-up finds.

Stopping wound care early: This matters inside the first two weeks. A wound that dries out, or a suture line strained by lifting, can split, and the scar is worse for it. Stopping sun protection over a fresh scar leaves a darker mark that can take a year or more to fade.

None of this produces a sudden change. The cost of stopping is that the next thing gets found later, when the surgery for it is bigger.

It is generally covered by health insurance when the tumor meets accepted criteria for Mohs, which is why the location, size and subtype are documented before it is booked. Professional societies publish appropriate use criteria that most insurers follow. Your share is your plan's deductible, copay and coinsurance.

Without insurance the total commonly runs into the thousands, with a range too wide for one figure to mean anything. Ask for a written estimate with the codes for the expected number of stages and the likely repair, and what happens to it if more stages are needed. Hospital-affiliated offices cost more than freestanding ones for the same work.

Mohs is performed by dermatologists who have completed a fellowship in Mohs micrographic surgery and dermatologic oncology. The point of that training is that one person removes the tissue and reads the slides. The surgery and the pathology are the same job here, and doing one without the other loses what makes the method work.

Fair questions to ask: whether the surgeon completed a Mohs fellowship, whether the slides are processed and read in the office on the day, how many stages they expect, who will do the repair and when, and what the scar will look like and where the line will sit.

Ask to see the pathology report: Your biopsy report carries the tumor type and subtype, and they are the reason Mohs is being recommended.

Red flags: tissue sent to an offsite laboratory or read by someone else on another day, no clear answer about fellowship training, insistence on Mohs for a small low-risk tumor on the trunk without explaining why, no discussion of the repair or the scar before the day, and any package that bundles a cosmetic procedure into cancer surgery.

Where to look: The American College of Mohs Surgery and the American Society for Dermatologic Surgery both list members.

• "Mohs is major surgery and I will be put under." It is done under local anesthetic while you are awake, and you go home the same day. The operation is small. The length of the appointment is what makes it feel large.
• "The appointment is long because the surgery takes hours." The cutting takes minutes per stage. The hours go to freezing, slicing, staining and reading tissue. Most of the day is a waiting room.
• "Any dermatologist can do Mohs." Mohs surgeons complete an additional fellowship after dermatology residency, because the same person removes the tissue and reads the slides. Asking about that training is reasonable.
• "Mohs is the best option for every skin cancer." It has the highest cure rate, and for a small low-risk tumor on the trunk it is more time, cost and process than the problem needs. A straightforward excision achieves the same outcome there.
• "They keep cutting until they hit something." Extra tissue is taken only where tumor showed on the map, and nowhere else. Removing the least normal skin possible is the entire point of the method.
• "People with deeper skin tones cannot have Mohs." The surgery and the cure rate are the same. What differs is scarring, and that is managed with how the wound is closed and how the scar is treated afterward.

1. Kofler L, Ziemer M, Andrulis M, et al. S1-Guideline: Microscopically controlled surgery. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. 2022. — Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2022
2. Bittner GC, Cerci FB, Kubo EM, et al. Mohs micrographic surgery: a review of indications, technique, outcomes, and considerations. Anais brasileiros de dermatologia. 2021. — Anais brasileiros de dermatologia, 2021
3. Tolkachjov SN, Kelley BF, Alahdab F, et al. Atypical fibroxanthoma: Systematic review and meta-analysis of treatment with Mohs micrographic surgery or excision. Journal of the American Academy of Dermatology. 2018. — Journal of the American Academy of Dermatology, 2018
4. Crum OM, O'Hern K, Demer AM, et al. Disease-Specific Mortality of Dermatofibrosarcoma Protuberans After Mohs Surgery Versus Wide Local Excision: A Systematic Review and Meta-Analysis. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 2024. — Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2024
5. Visconti MJ, Archibald LK, Shahwan KT, et al. Nasal reconstructive techniques following Mohs surgery or excisions: a systematic review. Archives of dermatological research. 2023. — Archives of dermatological research, 2023
6. Jeha GM, Malinosky HR, Taylor L, et al. Liposomal and Nonliposomal Bupivacaine for Mohs Surgery: A Systematic Review. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 2024. — Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2024